STAT1 and STAT6 Act as Antagonistic Regulators of PPARγ in Diabetic Patients with and without Cardiovascular Diseases

Area of Science:

• Endocrinology
• Molecular Biology
• Cardiovascular Disease Research

Background:

• Diabetes mellitus (T2DM) and atherosclerosis involve complex inflammatory processes.
• Peroxisome proliferator-activated receptors (PPARs), particularly PPARγ, regulate lipid metabolism and are implicated in T2DM and atherosclerosis.
• PPARγ activity is modulated by diabetes, with fatty acid translocase CD36 as a key target.

Purpose of the Study:

• To investigate the role of signal transducer and activator of transcription (STAT) 1 and STAT6 signaling in PPARγ-mediated lipid metabolism modulation in diabetic patients.
• To explore the differential expression of PPARγ, CD36, STAT1, and STAT6 in diabetic patients with and without cardiovascular diseases (CVD).

Main Methods:

• Real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) was employed.
• Target gene expression was quantified in Peripheral Blood Mononuclear Cells (PBMCs).
• Two groups of diabetic patients were studied: those with cardiovascular diseases (D.CVD) and those without (D).

Main Results:

• PPARγ and CD36 mRNA expression were significantly downregulated in D.CVD patients compared to D patients (p = 0.002; p = 0.04, respectively).
• Downregulated CD36 correlated with elevated plasma triglyceride (TG) levels in D.CVD patients.
• STAT1 expression was significantly higher in D.CVD patients (p = 0.01), while STAT6 induced significant PPARγ mRNA expression in D patients (p = 0.01).

Conclusions:

• PPARγ expression and CD36 mediation in PBMCs differ between diabetic patients with and without cardiovascular diseases.
• STAT6 and STAT1 signaling pathways play distinct roles in modulating PPARγ activity and lipid metabolism in diabetic patients with varying cardiovascular risk.
• These findings highlight potential molecular targets for managing lipid metabolism and cardiovascular complications in diabetes.